{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:11:03Z","timestamp":1785402663692,"version":"3.56.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpet.2026.104965","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:16:31Z","timestamp":1781626591000},"page":"104965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiproliferative effects of HIV integrase strand transfer inhibitors in experimental models for cancer research: A narrative review"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-3376","authenticated-orcid":false,"given":"Isabella","family":"Zanella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Manenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cesanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Codenotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7475-2668","authenticated-orcid":false,"given":"Alessandro","family":"Fanzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2026.104965_bib1","series-title":"World Cancer Report: Cancer Research for Cancer Prevention","year":"2020"},{"issue":"3","key":"10.1016\/j.jpet.2026.104965_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.jpet.2026.104965_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.jpet.2026.104965_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jpet.2026.104965_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol Res"},{"issue":"9939","key":"10.1016\/j.jpet.2026.104965_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jpet.2026.104965_bib9","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.jpet.2026.104965_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ijc.35493","article-title":"Cancer incidence in people with HIV in Italy: comparison of the ICONA COHORT with general population data","volume":"157","author":"Piselli","year":"2025","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2026.104965_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094768","article-title":"Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study","volume":"9","author":"Gotti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2026.104965_bib12","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.32158","article-title":"Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base","volume":"125","author":"Coghill","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jpet.2026.104965_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101613","article-title":"Incidence and mortality of non-AIDS-defining cancers among people living with HIV: a systematic review and meta-analysis","volume":"52","author":"Yuan","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jpet.2026.104965_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.32260","article-title":"Cervical cancer risk in women living with HIV across four continents: a multicohort study","volume":"146","author":"Rohner","year":"2020","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/j.jpet.2026.104965_bib15","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1097\/QAD.0000000000002003","article-title":"AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents","volume":"32","year":"2018","journal-title":"AIDS"},{"issue":"14","key":"10.1016\/j.jpet.2026.104965_bib16","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.3390\/cancers15143640","article-title":"Trends in cancer incidence in different antiretroviral treatment-eras amongst people with HIV","volume":"15","author":"Greenberg","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.jpet.2026.104965_bib17","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.2174\/0929867328666210114124744","article-title":"Recent advances in small-molecule HIV-1 integrase inhibitors","volume":"28","author":"Zhang","year":"2021","journal-title":"Curr Med Chem"},{"issue":"11","key":"10.1016\/j.jpet.2026.104965_bib18","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1007\/s12035-021-02508-5","article-title":"Dolutegravir inhibition of matrix metalloproteinases affects mouse neurodevelopment","volume":"58","author":"Bade","year":"2021","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104965_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac029","article-title":"Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting","volume":"9","author":"Greenberg","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"10281","key":"10.1016\/j.jpet.2026.104965_bib20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jpet.2026.104965_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202400898","article-title":"Repurposing antiviral drugs as potential anti-EGFR agents in NSCLC: a structure-based screening and molecular dynamics analysis","volume":"21","author":"Adegboyega","year":"2024","journal-title":"Chem Biodivers"},{"issue":"7","key":"10.1016\/j.jpet.2026.104965_bib22","article-title":"Dolutegravir inhibits proliferation and motility of BT-20 tumor cells through inhibition of human endogenous retrovirus type K","volume":"14","author":"Li","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.jpet.2026.104965_bib23","first-page":"1","article-title":"Antiretroviral therapy and cancers: dolutegravir, ritonavir and zidovudine have toxic effects on the viability of Cal-27 cancer cell line","volume":"9","author":"McNeil","year":"2024","journal-title":"Med Clin Res"},{"key":"10.1016\/j.jpet.2026.104965_bib24","article-title":"Comprehensive analysis of the progression mechanisms of CRPC and its inhibitor discovery based on machine learning algorithms","volume":"14","author":"Wang","year":"2023","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib25","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1038\/s41598-026-40136-y","article-title":"Deciphering the groove-binding mode of dolutegravir with salmon sperm DNA through spectroscopic and molecular modelling approaches","volume":"16","author":"Yosrey","year":"2026","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2026.104965_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"51","key":"10.1016\/j.jpet.2026.104965_bib27","doi-asserted-by":"crossref","first-page":"84093","DOI":"10.18632\/oncotarget.11455","article-title":"Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpet.2026.104965_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112085","article-title":"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities","volume":"190","author":"Sun","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2026.104965_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103392","article-title":"Synthesis and biological evaluation of 1-(benzofuran-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazole derivatives as tubulin polymerization inhibitors","volume":"94","author":"Qi","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jpet.2026.104965_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.849364","article-title":"Design, synthesis, and antitumor activity of erlotinib derivatives","volume":"13","author":"Mao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104965_bib31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/molecules29081779","article-title":"Discovery of dolutegravir derivative against liver cancer via inducing autophagy and DNA damage","volume":"29","author":"Hou","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.jpet.2026.104965_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105129","article-title":"Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway","volume":"161","author":"Wang","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13065-024-01205-3","article-title":"Synthesis and antitumor activity of dolutegravir derivatives bearing 1,2,3-triazole moieties","volume":"18","author":"Hou","year":"2024","journal-title":"BMC Chem"},{"key":"10.1016\/j.jpet.2026.104965_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106926","article-title":"Discovery of dolutegravir-1,2,3-triazole derivatives against prostate cancer via inducing DNA damage","volume":"141","author":"Zhou","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jpet.2026.104965_bib35","series-title":"Cancer: Disease Control Priorities, Third Edition (Volume 3)","author":"Gelband","year":"2015"},{"issue":"2","key":"10.1016\/j.jpet.2026.104965_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000519861","article-title":"Metastatic prostate cancer: treatment options","volume":"100","author":"Achard","year":"2022","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.jpet.2026.104965_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/TCRM.S2268","article-title":"Raltegravir: first in class HIV integrase inhibitor","volume":"4","author":"Temesgen","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"18","key":"10.1016\/j.jpet.2026.104965_bib39","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.jpet.2026.104965_bib40","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","article-title":"Adverse events of raltegravir and dolutegravir","volume":"31","author":"Elzi","year":"2017","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jpet.2026.104965_bib41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3390\/cancers13040861","article-title":"The FDA-approved antiviral raltegravir inhibits fascin1-dependent invasion of colorectal tumor cells in vitro and in vivo","volume":"13","author":"Alburquerque-Gonz\u00e1lez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2026.104965_bib42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/cbdd.14237","article-title":"HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma","volume":"102","author":"Akcora-Yildiz","year":"2023","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"10.1016\/j.jpet.2026.104965_bib43","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s11030-025-11119-4","article-title":"Machine learning-based screening and molecular simulations for discovering novel PARP-1 inhibitors targeting DNA repair mechanisms for breast cancer therapy","volume":"29","author":"Shahab","year":"2025","journal-title":"Mol Divers"},{"issue":"18","key":"10.1016\/j.jpet.2026.104965_bib44","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-18-4080","article-title":"Therapeutic targeting of aldolase A interactions inhibits lung cancer metastasis and prolongs survival","volume":"79","author":"Chang","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.104965_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1741-7015-11-52","article-title":"Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis","volume":"11","author":"Tan","year":"2013","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104965_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5603\/AHP.2022.0010","article-title":"Incidence and disease prevalence for lymphoid neoplasms in poland","volume":"53","author":"Giannopoulos","year":"2022","journal-title":"Acta Haematol Pol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104965_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jpet.2026.104965_bib48","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jpet.2026.104965_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106931","article-title":"Gene therapy strategies for RAG1 deficiency: challenges and breakthroughs","volume":"270","author":"Gilioli","year":"2024","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.jpet.2026.104965_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.237","article-title":"HIV integrase inhibitor, elvitegravir, impairs RAG functions and inhibits V(D)J recombination","volume":"8","author":"Nishana","year":"2017","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1073\/pnas.012610699","article-title":"Effect of HIV integrase inhibitors on the RAG1\/2 recombinase","volume":"99","author":"Melek","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpet.2026.104965_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41420-020-0281-4","article-title":"Biochemical activity of RAGs is impeded by dolutegravir, an HIV integrase inhibitor","volume":"6","author":"Nilavar","year":"2020","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.jpet.2026.104965_bib54","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/ijms25031615","article-title":"Lamivudine, doravirine, and cabotegravir downregulate the expression of human endogenous retroviruses (HERVs), inhibit cell growth, and reduce invasive capability in melanoma cell lines","volume":"25","author":"Zanr\u00e8","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.jpet.2026.104965_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252211939","article-title":"BRAF-mutated melanoma cell lines develop distinct molecular signatures after prolonged exposure to AZ628 or dabrafenib: potential benefits of the antiretroviral treatments cabotegravir or doravirine on BRAF-inhibitor-resistant cells","volume":"25","author":"Zanr\u00e8","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jpet.2026.104965_bib56","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","article-title":"The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031","volume":"136","author":"Whiteman","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104965_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006451","article-title":"A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion","volume":"13","author":"Lema\u00eetre","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jpet.2026.104965_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1265289","article-title":"Design and synthesis of cabotegravir derivatives bearing 1,2,3-triazole and evaluation of anti-liver cancer activity","volume":"14","author":"Xie","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2026.104965_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117856","article-title":"Novel 1,2,3-triazole-based compound triggers apoptosis through DNA damage response involving ATM\/ATR signaling in liver cancer cells","volume":"248","author":"Lu","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2026.104965_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1265245","article-title":"Synthesis and biological evaluation of novel 1,2,3-triazole hybrids of cabotegravir: identification of potent antitumor activity against lung cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.jpet.2026.104965_bib61","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/0008-5472.CAN-21-4124","article-title":"Anti-HIV drug elvitegravir suppresses cancer metastasis via increased proteasomal degradation of m6A methyltransferase METTL3","volume":"82","author":"Liao","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.104965_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/ebm.2026.10988","article-title":"Training the next-generation of biomedical scientists through artificial intelligence-driven education and research in pharmacology and pharmaceutical sciences","volume":"251","author":"Kumar","year":"2026","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"10.1016\/j.jpet.2026.104965_bib63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.jpet.2026.104965_bib64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12032-025-02994-w","article-title":"Drug repurposing in oncology: a path beyond the bottleneck","volume":"42","author":"Sajwani","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.jpet.2026.104965_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1763769","article-title":"Recent advances in drug repurposing for cancer immunomodulation emerging strategies, mechanistic insights, and clinical translation","volume":"16","author":"Malik","year":"2026","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104965_bib66","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-18-0666","article-title":"The use of ribavirin as an anticancer therapeutic: will it go viral?","volume":"18","author":"Casaos","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.jpet.2026.104965_bib67","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/bcp.70113","article-title":"Approaches to repurposing reverse transcriptase antivirals in cancer","volume":"91","author":"Head","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"19","key":"10.1016\/j.jpet.2026.104965_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914631","article-title":"Exploring HERV-K (HML-2) influence in cancer and prospects for therapeutic interventions","volume":"24","author":"Costa","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12977-017-0347-4","article-title":"Inhibition of human endogenous retrovirus-K by antiretroviral drugs","volume":"14","author":"Tyagi","year":"2017","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/j.jpet.2026.104965_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29532","article-title":"Development of human endogenous retrovirus type K- related treatments for human diseases","volume":"96","author":"Dai","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.jpet.2026.104965_bib71","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.3390\/ijms25094640","article-title":"Dolutegravir and folic acid interaction during neural system development in zebrafish embryos","volume":"25","author":"Zizioli","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.jpet.2026.104965_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1113032","article-title":"Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors","volume":"5","author":"Foster","year":"2023","journal-title":"Front Toxicol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104965_bib73","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s43018-024-00739-8","article-title":"Cycling back to folate metabolism in cancer","volume":"5","author":"Lee","year":"2024","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.jpet.2026.104965_bib74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","article-title":"Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02468-24","article-title":"Lack of activity of HIV-1 integrase strand-transfer inhibitors on recombinase activating gene (RAG) activity at clinically relevant concentrations","volume":"13","author":"Demirdjian","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"36","key":"10.1016\/j.jpet.2026.104965_bib76","doi-asserted-by":"crossref","first-page":"14747","DOI":"10.1073\/pnas.1305066110","article-title":"Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations","volume":"110","author":"Varadarajan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jpet.2026.104965_bib77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/hiv.12557","article-title":"Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens","volume":"19","author":"Cozzi-Lepri","year":"2018","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.jpet.2026.104965_bib78","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaoncol.2025.1589","article-title":"Cancer incidence and trends in US adults with HIV","volume":"11","author":"Haas","year":"2025","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104965_bib79","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1093\/cid\/ciaf248","article-title":"Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicenter, observational cohort","volume":"81","author":"Han","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104965_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/M16-0240","article-title":"Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study","volume":"166","author":"Wang","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jpet.2026.104965_bib81","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/hiv.12034","article-title":"Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999\u20132009","volume":"14","author":"Calabresi","year":"2013","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.jpet.2026.104965_bib82","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/cid\/cix480","article-title":"AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: a multiregional multicohort study","volume":"65","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:20:52Z","timestamp":1785399652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652601164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S002235652601164X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104965","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiproliferative effects of HIV integrase strand transfer inhibitors in experimental models for cancer research: A narrative review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104965"}}